E-LIB Suche - Ergebnisse für: Oriol, A

1

The genomic profiling of high-risk smoldering myeloma patie..:

Medina-Herrera, A. ; Vazquez, I. ; Cuenca, I....
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSE..:

van de Donk, N. ; Rasche, L. ; Touzeau, C....
HemaSphere. 7 (2023) S2 - p. 34-34 , 2023

Link: https://doi.org/10.1097/..

3

HPR9 Value Criteria for Outcomes Based Managed Entry Agreem..:

Poveda, J.L. ; Mateos, M.V. ; Trillo, J.L....
Value in Health. 26 (2023) 12 - p. S256 , 2023

Link: https://doi.org/10.1016/..

4

CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC)..:

Moreau, P. ; Usmani, S.Z. ; van de Donk, N.W.C.J....
Value in Health. 26 (2023) 12 - p. S31 , 2023

Link: https://doi.org/10.1016/..

5

P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) ..:

Moreau, P. ; Usmani, S.Z. ; van de Donk, N.W.C.J....
Value in Health. 26 (2023) 12 - p. S5-S6 , 2023

Link: https://doi.org/10.1016/..

6

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED R..:

Minnema, M.C. ; Chari, A. ; Touzeau, C....
HemaSphere. 7 (2023) S2 - p. 26-27 , 2023

Link: https://doi.org/10.1097/..

7

S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL,..:

Rodriguez Otero, P. ; D'Souza, A. ; Reece, D....
HemaSphere. 6 (2022) - p. 89-90 , 2022

Link: https://doi.org/10.1097/..

8

P945: SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY ..:

Quach, H. ; Parmar, G. ; Ocio, E. M....
HemaSphere. 6 (2022) - p. 835-836 , 2022

Link: https://doi.org/10.1097/..

9

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS S..:

Usmani, S ; Alonso, A ; Quach, H...
HemaSphere. 6 (2022) - p. 19-19 , 2022

Link: https://doi.org/10.1097/..

10

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF..:

van de Donk, N. W. C. J ; Popat, R ; Hulin, C...
HemaSphere. 6 (2022) - p. 14-15 , 2022

Link: https://doi.org/10.1097/..

11

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS ..:

Usmani, S. Z. ; Mielnik, M. ; Koh, Y....
HemaSphere. 6 (2022) - p. 832-833 , 2022

Link: https://doi.org/10.1097/..

12

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUM..:

Mateos, M ; Hari, P ; Bahlis, N...
HemaSphere. 6 (2022) - p. 9-9 , 2022

Link: https://doi.org/10.1097/..

13

Corrigendum to P-207: A multi-center, phase 1b study to ass..:

Moreau, Philippe ; Parmar, Gurdeep ; Prince, Miles...
Clinical Lymphoma Myeloma and Leukemia. , 2022

Link: https://doi.org/10.1016/..

14

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF..:

Popat, R ; Usmani, S ; Garfall, A...
HemaSphere. 6 (2022) - p. 14-14 , 2022

Link: https://doi.org/10.1097/..

15

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS ..:

Rosinol, L. ; Usmani, S. Z. ; Bahlis, N....
HemaSphere. 6 (2022) - p. 1885-1886 , 2022

Link: https://doi.org/10.1097/..